BidaskClub upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a sell rating to a hold rating in a report issued on Tuesday morning, BidAskClub reports.

Several other research firms also recently commented on ADAP. Raymond James reduced their price objective on Adaptimmune Therapeutics from $16.00 to $6.00 and set an outperform rating on the stock in a report on Tuesday, May 7th. Svb Leerink restated a market perform rating and set a $5.00 price objective (down from $12.00) on shares of Adaptimmune Therapeutics in a report on Tuesday, May 7th. Zacks Investment Research upgraded Adaptimmune Therapeutics from a hold rating to a buy rating and set a $6.00 price objective on the stock in a report on Wednesday, February 13th. Citigroup restated a buy rating and set a $8.00 price objective on shares of Adaptimmune Therapeutics in a report on Thursday, May 30th. Finally, ValuEngine downgraded Adaptimmune Therapeutics from a hold rating to a sell rating in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $6.81.

ADAP opened at $3.63 on Tuesday. The firm has a market cap of $380.03 million, a price-to-earnings ratio of -3.78 and a beta of 1.56. Adaptimmune Therapeutics has a 52 week low of $3.20 and a 52 week high of $14.54. The company has a current ratio of 8.55, a quick ratio of 8.55 and a debt-to-equity ratio of 0.12.

Adaptimmune Therapeutics (NASDAQ:ADAP) last released its quarterly earnings data on Monday, May 6th. The biotechnology company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Adaptimmune Therapeutics had a negative return on equity of 45.03% and a negative net margin of 161.09%. On average, equities research analysts forecast that Adaptimmune Therapeutics will post -1.17 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its position in Adaptimmune Therapeutics by 157.3% during the 4th quarter. SG Americas Securities LLC now owns 20,004 shares of the biotechnology company’s stock valued at $115,000 after acquiring an additional 12,229 shares in the last quarter. Raymond James & Associates boosted its position in Adaptimmune Therapeutics by 59.0% during the 4th quarter. Raymond James & Associates now owns 22,906 shares of the biotechnology company’s stock valued at $132,000 after acquiring an additional 8,498 shares in the last quarter. Henry James International Management Inc. bought a new stake in Adaptimmune Therapeutics during the 4th quarter valued at $144,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in Adaptimmune Therapeutics by 139.9% during the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 26,341 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 15,361 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new stake in Adaptimmune Therapeutics during the 4th quarter valued at $219,000. 66.30% of the stock is currently owned by institutional investors and hedge funds.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.

Read More: Hedge Funds – How They Work For Investors

Analyst Recommendations for Adaptimmune Therapeutics (NASDAQ:ADAP)

Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.